Stocksigma LogoStocksigma Logo

Alkem Laboratories Launches NeuCeno for Partial-Onset Seizure Treatment in India

On 16th Sep'26, Alkem Laboratories announced the launch of NeuCeno (cenobamate) in India for treating partial-onset seizures in adults, marking the

Alkem Laboratories Launches NeuCeno for Partial-Onset Seizure Treatment in India

Alkem Laboratories Ltd 路 Press Release 路 16 Sept 2026, 5:19 pm

Alkem Laboratories Launches NeuCeno for Partial-Onset Seizure Treatment in India On 16th Sep'26, Alkem Laboratories announced the launch of NeuCeno (cenobamate) in India for treating partial-onset seizures in adults, marking the molecule's first entry into the domestic market. NeuCeno is a once-daily oral anti-seizure medication available in dosages ranging from 12.5 mg to 200 mg. Clinical data demonstrated up to a 78% reduction in seizure frequency, with up to 30% of patients achieving seizure freedom during the maintenance phase, targeting an estimated 9.4 million epilepsy patients across India.

Original exchange filing (PDF)

More announcements from Alkem Laboratories Ltd

All Alkem Laboratories Ltd announcements